Published in Cancer Weekly, August 31st, 2004
Under the terms of the agreement, both partners will participate in a 3-year, renewable research program aimed at completing characterization of the antitumor activity of F50035 and identifying back-up antibodies.
Merck will be responsible for development and manufacturing of F50035. Merck is receiving worldwide marketing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.